Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals Inc (NAVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,404
  • Shares Outstanding, K 100,084
  • Annual Sales, $ 70 K
  • Annual Income, $ -15,180 K
  • 60-Month Beta 1.13
  • Price/Sales 345.39
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NAVB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.21
  • Most Recent Earnings $-0.02 on 11/14/23
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0330 +33.33%
on 04/12/24
0.0600 -26.67%
on 04/15/24
+0.0030 (+7.32%)
since 03/22/24
3-Month
0.0301 +46.18%
on 02/12/24
0.0638 -31.03%
on 01/25/24
-0.0140 (-24.14%)
since 01/22/24
52-Week
0.0210 +109.52%
on 10/06/23
0.2760 -84.06%
on 04/28/23
-0.2115 (-82.78%)
since 04/21/23

Most Recent Stories

More News
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals to Host Fourth Quarter 2022 Earnings Conference Call and Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company’s Cancer Immunotherapy Pipeline

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals Files Appeal in CRG Case

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.0440 (+25.71%)
Navidea Biopharmaceuticals Reports Third Quarter 2022 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.0440 (+25.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and...

See More

Key Turning Points

3rd Resistance Point 0.0640
2nd Resistance Point 0.0570
1st Resistance Point 0.0505
Last Price 0.0440
1st Support Level 0.0370
2nd Support Level 0.0300
3rd Support Level 0.0235

See More

52-Week High 0.2760
Fibonacci 61.8% 0.1786
Fibonacci 50% 0.1485
Fibonacci 38.2% 0.1184
Last Price 0.0440
52-Week Low 0.0210

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar